Search by Drug Name or NDC
NDC 50090-0934-00 FLOVENT 220 ug/1 Details
FLOVENT 220 ug/1
FLOVENT is a RESPIRATORY (INHALATION) AEROSOL, METERED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by A-S Medication Solutions. The primary component is FLUTICASONE PROPIONATE.
MedlinePlus Drug Summary
Fluticasone oral inhalation is used to prevent difficulty breathing, chest tightness, wheezing, and coughing caused by asthma in adults and children. It is in a class of medications called corticosteroids. Fluticasone works by decreasing swelling and irritation in the airways to allow for easier breathing.
Related Packages: 50090-0934-00Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Fluticasone Oral Inhalation
Product Information
NDC | 50090-0934 |
---|---|
Product ID | 50090-0934_a17632f6-f73b-4e4d-aa36-535d86388153 |
Associated GPIs | 44400033223240 |
GCN Sequence Number | 021483 |
GCN Sequence Number Description | fluticasone propionate AER W/ADAP 220 MCG INHALATION |
HIC3 | B6M |
HIC3 Description | GLUCOCORTICOIDS, ORALLY INHALED |
GCN | 53639 |
HICL Sequence Number | 007873 |
HICL Sequence Number Description | FLUTICASONE PROPIONATE |
Brand/Generic | Generic |
Proprietary Name | FLOVENT |
Proprietary Name Suffix | HFA |
Non-Proprietary Name | fluticasone propionate |
Product Type | HUMAN PRESCRIPTION DRUG |
Dosage Form | AEROSOL, METERED |
Route | RESPIRATORY (INHALATION) |
Active Ingredient Strength | 220 |
Active Ingredient Units | ug/1 |
Substance Name | FLUTICASONE PROPIONATE |
Labeler Name | A-S Medication Solutions |
Pharmaceutical Class | Corticosteroid Hormone Receptor Agonists [MoA], Corticosteroid [EPC] |
DEA Schedule | n/a |
Marketing Category | NDA |
Application Number | NDA021433 |
Listing Certified Through | 2024-12-31 |
Package
NDC 50090-0934-00 (50090093400)
NDC Package Code | 50090-0934-0 |
---|---|
Billing NDC | 50090093400 |
Package | 1 INHALER in 1 CARTON (50090-0934-0) / 120 AEROSOL, METERED in 1 INHALER |
Marketing Start Date | 2014-11-28 |
NDC Exclude Flag | N |
Pricing Information | N/A |